The tweet was deleted by the author.
But we saved everything 🙂.
Brandon Beylo highlights strong performance in the biotech sector, observing that biotech stocks demonstrated resilience despite volatility around the FOMC meeting.
Beylo suggests that such strength often points to the emergence of new market leaders, and shares that he is beginning to build a basket of biotech names.
Beylo has recently commented on other assets, noting that gold traded below its 200-day average for the first time since 2023, which he viewed as a potential long-term buying opportunity here. He previously suggested that gold prices could bottom near $3,800 per ounce before recovering here. These observations come as he shifts focus to building positions in biotech stocks.